Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

BOTHELL, Wash. and VANCOUVER, Aug. 4, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an update on current events and activities and announced its second quarter financial results.

Second Quarter 2011 Highlights

  • Expected timing of results from the survival primary endpoint for the custirsen SYNERGY Phase 3 clinical trial remains unchanged at Q4 2013.
  • During discussions regarding the SATURN Special Protocol Assessment, or SPA, amendment, FDA stated that an application supported primarily by the results of SYNERGY alone would be acceptable for submission.
  • We have revised the custirsen SATURN Phase 3 trial protocol to expand the eligible patient population, and to align with the recently approved chemotherapy, cabazitaxel.
  • We are awaiting final, written FDA agreement on the SPA amendment that will allow patients to receive either docetaxel re-treatment or cabazitaxel as second-line chemotherapy.
  • Recruitment efforts are ongoing to enroll more patients in the SATURN study, which has had few patients accrued due to restrictive enrollment criteria regarding docetaxel retreatment and stable pain criteria. Expected timing of results for the pain palliation primary endpoint is now projected to be Q4 2013 rather than Q2 2013.
  • The initiation of the Phase 3 clinical trial evaluating custirsen in patients with non-small cell lung cancer (NSCLC) has been delayed as we determine the optimal chemotherapeutic combination based on safety considerations and the current and evolving standard of care.
  • We believe NSCLC is a promising indication and remain committed to the advancement of custirsen in NSCLC.
  • OGX-427
  • Enrollment continues for both the investigator-sponsored, randomized Phase 2 clinical trial evaluating OGX-427 in patients with castrate-resistant prostate cancer, an
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
    2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
    3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
    4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
    5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
    6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
    8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
    9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
    10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
    11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/22/2014)... JUNCTION, N.J. , Nov. 21, 2014 /PRNewswire/ ... company commercializing its European Union approved CytoSorb® cytokine ... worldwide, was awarded the Beacon of Light Award ... Awards Celebration.  Dr. Phillip ... "It is an honor to be recognized by ...
    (Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired by ... months and the 3 rd quarter sales ended September ... was $448,000 for the nine months ended September 2014 and ... though our 3 rd quarter is usually a seasonable ... from July into September for many countries worldwide, we are ...
    (Date:11/21/2014)... , Nov. 21, 2014  Alere Inc. (NYSE: ... diagnostic tests, has appointed Juliet Cunningham as ... Cunningham will be responsible for driving communications with the ... on a series of changes to increase shareholder value, ... to investors," said Namal Nawana, Chief Executive Officer. "We ...
    Breaking Medicine Technology:CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3Alere Appoints Juliet Cunningham to Lead Investor Relations 2
    ... organiser UBM Live , a division of UBM ... and Supply Chain Zone to be introduced at ICSE ... outsourcing. ICSE will take place from October 25-27, 2011 ... the world,s leading platform of pharmaceutical events, including CPhI ...
    ... GRAND RAPIDS, Mich., May 31, 2011 The ... announced the opening of a first-of-its-kind genomic-based clinical ... specifically relapsed and refractory neuroblastoma. ... Institute (VARI), is a nationwide network of pediatric ...
    Cached Medicine Technology:Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 2Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 3Consortium Opens Landmark Personalized Medicine Children's Cancer Trial 2
    (Date:11/23/2014)... To show thanks to new and old ... white evening dresses for weddings. Customers who need ... iFitDress.com is a distinguished dress manufacturer, and it is among ... customers for a very long time. The CEO of this ... will be able to buy not only a beautiful dress, ...
    (Date:11/23/2014)... (PRWEB) November 23, 2014 AngelWeddingDress.com ... worldwide a new selection of beach wedding dresses. “If ... best prices, visit AngelWeddingDress.com as soon as possible. Here ... workmanship.” The sales manager says. , Holding a big ... girl. And choosing a beautiful beach wedding dress is ...
    (Date:11/23/2014)... (PRWEB) November 23, 2014 The FDA ... in Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? ... , The FDA’s focus on promotional activities is no ... , Now they're looking at websites, Twitter, journal articles, ... calendar for Thursday, Dec. 11, for On-Demand access to ...
    (Date:11/23/2014)... , the world’s leader in bamboo flooring, has recently released ... Now, the business is announcing big discounts on these new ... until Dec. 20, 2014. , The new click strand woven ... makes it very easy to maintain. As one of the ... its website the best shopping platform for people who are ...
    (Date:11/22/2014)... Greenville, Sc (PRWEB) November 23, 2014 ... officially opened its doors in the downtown Greenville area. ... of Downtown Greenville , decided to open her own ... such amazing results with the patients. , AlignLife ... the proper tools. With a focus on chiropractic care ...
    Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2
    ... 'Bigorexic'? No, its not another eating disorder, it's just ... Bruce Davies, of the University of Glamorgan //says that ... faced by people suffering from anorexia and bulimia. ... drugs to counteract their altered body images," he said. ...
    ... in the Bombay High Court today raised the issue of spurious ... curb the trade of such drugs. // ,The High ... this regard by July 12., ,The PIL was filed by ... spurious injection of the drug `Imipenam' at KEM hospital in Pune ...
    ... Zealand report low levels of perceived security at school, ... a new survey//. ,The Youth 2000 national survey, ... Auckland University, asked 922 Asian students about their mental ... ,Chinese and Indian students made up the ...
    ... fat in abdomen, hip and upper thighs through liposuction which ... a liquid and is sucked out. // ,Liposuction ... special instruments and technique are used to liquefy the fat ... the fatty areas. Since it is practically non-invasive it is ...
    ... doctor, Dr.S.Raja Sabapathy, has been appointed honorary consultant and ... speciality of plastic, hand and reconstructive micro surgery. // ... of surgery in Ganga Medical Centre and Hospitals, would ... of armed forces across the country, an hospital release ...
    ... a very common cancer which has very poor prognosis. This is ... spread in the body//. The spread of cancer cells in the ... in case of cancer patients as it blocks vital organs, blood ... and treatment of cancer patients improves their survival rate. But good ...
    Cached Medicine News:Health News:Indian Students in New Zealand Feel Insecure 2Health News:IMP3 the Novel Biomarker for Metastatic Cancer 2Health News:IMP3 the Novel Biomarker for Metastatic Cancer 3
    The Elisa test is used for the detection and semi-quantitative determination of IgG, antibodies to myeloperoxidase in human sera as an aid to the diagnosis is of microscopic polyangiitis....
    ... this Enzyme ImmunoAssay (EIA) is as follows: ... on a 96 well microtiter plate. After ... the trapped molecule is covalently linked to ... After washing and denaturing treatment, Angiotensin II ...
    ... a solid phase two-site enzyme immunoassay. ... sandwich technique in which two monoclonal ... determinants on the insulin molecule. During ... with peroxidase-conjugated anti-insulin antibodies and anti-insulin ...
    ... SAS RSV antigen test is ... for the presumptive qualitative detection ... from nasopharyngeal specimens in neonatal ... 15 minute test has a ...
    Medicine Products: